{"DataElement":{"publicId":"7092946","version":"1","preferredName":"T-Cell Depletion Method  Performed Type","preferredDefinition":"Treatment to destroy T cells, which play an important role in the immune response. Elimination of T cells from a bone marrow graft from a donor may reduce the chance of an immune reaction against the recipient's tissues._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Executed and carried through to completion._Something distinguishable as an identifiable class based on common qualities.","longName":"TCELL_DEP_MTD","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2774068","version":"1","preferredName":"T-Cell Depletion Method  Performed","preferredDefinition":"Treatment to destroy T cells, which play an important role in the immune response. Elimination of T cells from a bone marrow graft from a donor may reduce the chance of an immune reaction against the recipient's tissues._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._Executed and carried through to completion.","longName":"TCD_MTH_PERF","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2774065","version":"1","preferredName":"T-Cell Depletion Method","preferredDefinition":"Treatment to destroy T cells, which play an important role in the immune response. Elimination of T cells from a bone marrow graft from a donor may reduce the chance of an immune reaction against the recipient's tissues.:A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","longName":"C15699:C71460","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Depletion Therapy","conceptCode":"C15699","definition":"Treatment to destroy T cells, which play an important role in the immune response. Elimination of T cells from a bone marrow graft or peripheral blood stem cell graft from a donor may reduce the chance of an immune reaction against the recipient's tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Method","conceptCode":"C71460","definition":"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"544A2074-E111-3918-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-12","modifiedBy":"ONEDATA","dateModified":"2008-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241241","version":"1","preferredName":"Performed","preferredDefinition":"Performed; carried out.","longName":"C38000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FA7953-8839-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-08","modifiedBy":"ONEDATA","dateModified":"2005-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435033","version":"1","preferredName":"Techniques","preferredDefinition":"A practiced and regimented skill or series of actions.","longName":"C16847","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87DA-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"544A2074-E133-3918-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7092939","version":"1","preferredName":"Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"7092939v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6431768","version":"1","preferredName":"Other","longName":"6431768v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"762A692A-EEF7-29A1-E053-F662850A9EA9","latestVersionIndicator":"Yes","beginDate":"2018-09-18","endDate":null,"createdBy":"WINCHC","dateCreated":"2018-09-18","modifiedBy":"GDEEN","dateModified":"2024-01-22","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D9934D-48BA-2D3D-E053-F662850AF9C5","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Alpha-beta depletion","valueDescription":"Alpha-beta depletion","ValueMeaning":{"publicId":"7092940","version":"1","preferredName":"Alpha-beta depletion","longName":"7092940","preferredDefinition":"Alpha-beta depletion","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D9934D-48C4-2D3D-E053-F662850AF9C5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D9934D-48DD-2D3D-E053-F662850AF9C5","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"CD34-positive selection","valueDescription":"CD34-positive selection","ValueMeaning":{"publicId":"7092941","version":"1","preferredName":"CD34-positive selection","longName":"7092941","preferredDefinition":"CD34-positive selection","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D9934D-48E7-2D3D-E053-F662850AF9C5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D9934D-4900-2D3D-E053-F662850AF9C5","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Abatacept","valueDescription":"Abatacept","ValueMeaning":{"publicId":"6429536","version":"1","preferredName":"Abatacept","longName":"6429536","preferredDefinition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abatacept","conceptCode":"C28898","definition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AF6CD8-495C-4E44-E053-F662850AD113","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D9934D-490A-2D3D-E053-F662850AF9C5","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"ATG","valueDescription":"ATG","ValueMeaning":{"publicId":"7092942","version":"1","preferredName":"ATG","longName":"7092942","preferredDefinition":"ATG","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D9934D-491E-2D3D-E053-F662850AF9C5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D9934D-4937-2D3D-E053-F662850AF9C5","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Alemtuzumab","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D9934D-4914-2D3D-E053-F662850AF9C5","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Post transplant cytoxan","valueDescription":"Post transplant cytoxan","ValueMeaning":{"publicId":"7092943","version":"1","preferredName":"Post transplant cytoxan","longName":"7092943","preferredDefinition":"Post transplant cytoxan","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D9934D-4941-2D3D-E053-F662850AF9C5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D9934D-495A-2D3D-E053-F662850AF9C5","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Ex vivo t cell depletion","valueDescription":"Ex vivo t cell depletion","ValueMeaning":{"publicId":"7092944","version":"1","preferredName":"Ex vivo t cell depletion","longName":"7092944","preferredDefinition":"Ex vivo t cell depletion","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D9934D-4964-2D3D-E053-F662850AF9C5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D9934D-497D-2D3D-E053-F662850AF9C5","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Log depletion of CD19+ B cells","valueDescription":"Log depletion of CD19+ B cells","ValueMeaning":{"publicId":"8177915","version":"1","preferredName":"Log depletion of CD19+ B cells","longName":"8177915","preferredDefinition":"Log depletion of CD19+ B cells","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDAF7CEE-1CD7-60EA-E053-4EBD850AC125","latestVersionIndicator":"Yes","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-27","modifiedBy":"ONEDATA","dateModified":"2022-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDAF7CEE-1CF0-60EA-E053-4EBD850AC125","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-27","modifiedBy":"ONEDATA","dateModified":"2022-04-27","deletedIndicator":"No"},{"value":"Log depletion of TCRαβ+ T cells","valueDescription":"Log depletion of TCRαβ+ T cells","ValueMeaning":{"publicId":"8177916","version":"1","preferredName":"Log depletion of TCRαβ+ T cells","longName":"8177916","preferredDefinition":"Log depletion of TCRαβ+ T cells","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDAF7CEE-1CFA-60EA-E053-4EBD850AC125","latestVersionIndicator":"Yes","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-27","modifiedBy":"ONEDATA","dateModified":"2022-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDAF7CEE-1D13-60EA-E053-4EBD850AC125","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-27","modifiedBy":"ONEDATA","dateModified":"2022-04-27","deletedIndicator":"No"},{"value":"CD20+ B cells/Kg","valueDescription":"B-Lymphocyte Antigen CD20","ValueMeaning":{"publicId":"3991503","version":"1","preferredName":"B-Lymphocyte Antigen CD20","longName":"3991503","preferredDefinition":"B-lymphocyte antigen CD20 (297 aa, ~33 kDa) is encoded by the human MS4A1 gene. This protein plays a role in both the activation and proliferation of B-cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B-Lymphocyte Antigen CD20","conceptCode":"C38896","definition":"B-lymphocyte antigen CD20 (297 aa, ~33 kDa) is encoded by the human MS4A1 gene. This protein plays a role in both the activation and proliferation of B-cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED596A54-CDD6-6922-E040-BB89AD437737","latestVersionIndicator":"Yes","beginDate":"2013-12-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-12-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDAF7CEE-1D27-60EA-E053-4EBD850AC125","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-27","modifiedBy":"ONEDATA","dateModified":"2022-04-27","deletedIndicator":"No"},{"value":"NK cells/Kg","valueDescription":"Natural Killer Cell","ValueMeaning":{"publicId":"5002432","version":"1","preferredName":"Natural Killer Cell","longName":"5002432","preferredDefinition":"A type of immune cell that has granules (small particles) with enzymes that can kill tumor cells or cells infected with a virus. A natural killer cell is a type of white blood cell.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Natural Killer Cell","conceptCode":"C12536","definition":"Natural killer cells are cells that resemble large granular lymphocytes.  They do not express markers of either T or B cell lineage. They are positive for CD16, CD56, and CD 94.  These cells do possess Fc receptors for IgG and can kill target cells using antibody-dependent cell-mediated cytotoxicity. They can also use perforin to kill cells in the absence of antibody and killing may occur without previous sensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F3DCDAD-0686-3CFA-E050-BB89AD436A35","latestVersionIndicator":"Yes","beginDate":"2015-09-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-09-08","modifiedBy":"LISU","dateModified":"2023-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDAF7CEE-1D3C-60EA-E053-4EBD850AC125","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-27","modifiedBy":"ONEDATA","dateModified":"2022-04-27","deletedIndicator":"No"},{"value":"Gamma delta T cells/Kg","valueDescription":"Gamma/Delta T-Lymphocyte","ValueMeaning":{"publicId":"4261913","version":"1","preferredName":"Gamma/Delta T-Lymphocyte","longName":"4261913","preferredDefinition":"A resting, mature T cell that probably plays a primary role in suppressor/cytotoxic phenomena.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gamma/Delta T-Lymphocyte","conceptCode":"C39585","definition":"A resting, mature T cell that probably plays a primary role in suppressor/cytotoxic phenomena.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62488D0-9971-BB0B-E040-BB89AD433713","latestVersionIndicator":"Yes","beginDate":"2014-04-03","endDate":null,"createdBy":"COLBERTM","dateCreated":"2014-04-03","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDAF7CEE-1D51-60EA-E053-4EBD850AC125","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-27","modifiedBy":"ONEDATA","dateModified":"2022-04-27","deletedIndicator":"No"},{"value":"Alpha beta T cells/Kg","valueDescription":"Alpha/Beta T-Lymphocyte","ValueMeaning":{"publicId":"6568668","version":"1","preferredName":"Alpha/Beta T-Lymphocyte","longName":"6568668","preferredDefinition":"A mature T-cell that expresses a T-cell receptor complex comprised of the highly variable alpha and beta chains complexed with the invariant CD3 antigen complex and plays a primary role in adaptive immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha/Beta T-Lymphocyte","conceptCode":"C156387","definition":"A mature T-cell that expresses a T-cell receptor complex comprised of the highly variable alpha and beta chains complexed with the invariant CD3 antigen complex and plays a primary role in adaptive immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B96EE86-F222-58F8-E053-F662850AC43C","latestVersionIndicator":"Yes","beginDate":"2018-11-26","endDate":null,"createdBy":"COLBERTM","dateCreated":"2018-11-26","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDAF7CEE-1D66-60EA-E053-4EBD850AC125","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-27","modifiedBy":"ONEDATA","dateModified":"2022-04-27","deletedIndicator":"No"},{"value":"Alpha beta T cells","valueDescription":"Alpha/Beta T-Lymphocyte","ValueMeaning":{"publicId":"6568668","version":"1","preferredName":"Alpha/Beta T-Lymphocyte","longName":"6568668","preferredDefinition":"A mature T-cell that expresses a T-cell receptor complex comprised of the highly variable alpha and beta chains complexed with the invariant CD3 antigen complex and plays a primary role in adaptive immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha/Beta T-Lymphocyte","conceptCode":"C156387","definition":"A mature T-cell that expresses a T-cell receptor complex comprised of the highly variable alpha and beta chains complexed with the invariant CD3 antigen complex and plays a primary role in adaptive immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B96EE86-F222-58F8-E053-F662850AC43C","latestVersionIndicator":"Yes","beginDate":"2018-11-26","endDate":null,"createdBy":"COLBERTM","dateCreated":"2018-11-26","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDB621C8-2928-1184-E053-4EBD850A834E","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"CD20+ B cells","valueDescription":"B-Lymphocyte Antigen CD20","ValueMeaning":{"publicId":"3991503","version":"1","preferredName":"B-Lymphocyte Antigen CD20","longName":"3991503","preferredDefinition":"B-lymphocyte antigen CD20 (297 aa, ~33 kDa) is encoded by the human MS4A1 gene. This protein plays a role in both the activation and proliferation of B-cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B-Lymphocyte Antigen CD20","conceptCode":"C38896","definition":"B-lymphocyte antigen CD20 (297 aa, ~33 kDa) is encoded by the human MS4A1 gene. This protein plays a role in both the activation and proliferation of B-cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED596A54-CDD6-6922-E040-BB89AD437737","latestVersionIndicator":"Yes","beginDate":"2013-12-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-12-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDB621C8-293E-1184-E053-4EBD850A834E","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"Gamma delta T cells","valueDescription":"Gamma/Delta T-Lymphocyte","ValueMeaning":{"publicId":"4261913","version":"1","preferredName":"Gamma/Delta T-Lymphocyte","longName":"4261913","preferredDefinition":"A resting, mature T cell that probably plays a primary role in suppressor/cytotoxic phenomena.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gamma/Delta T-Lymphocyte","conceptCode":"C39585","definition":"A resting, mature T cell that probably plays a primary role in suppressor/cytotoxic phenomena.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62488D0-9971-BB0B-E040-BB89AD433713","latestVersionIndicator":"Yes","beginDate":"2014-04-03","endDate":null,"createdBy":"COLBERTM","dateCreated":"2014-04-03","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDB621C8-2953-1184-E053-4EBD850A834E","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"CD19+ B cells","valueDescription":"CD19+ B Lymphocyte","ValueMeaning":{"publicId":"8178003","version":"1","preferredName":"CD19+ B Lymphocyte","longName":"8178003","preferredDefinition":"Vo value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CD19+ B Lymphocyte","conceptCode":"CL276925","definition":"Vo value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DDB621C8-295F-1184-E053-4EBD850A834E","latestVersionIndicator":"Yes","beginDate":"2022-04-28","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDB621C8-297A-1184-E053-4EBD850A834E","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"TCRαβ+ T cells","valueDescription":"T-Cell Receptor, Alpha-Beta","ValueMeaning":{"publicId":"3364661","version":"1","preferredName":"T-Cell Receptor, Alpha-Beta","longName":"3364661","preferredDefinition":"T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Receptor Alpha-Beta","conceptCode":"C17433","definition":"A heterodimeric complex comprised of the highly variable T-cell receptor (TCR) alpha and beta chain proteins, which are linked by interchain disulfide bonds. This membrane bound complex is expressed on the surface of most T-lymphocytes and is involved in the recognition of peptide antigens that are presented by major histocompatibility (MHC) proteins.  The alpha/beta dimer is non-covalently associated with the CD3 complex, which promotes ligand-dependent signaling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B74D806F-8CB2-C84F-E040-BB89AD430AB5","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-01-24","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDB621C8-298F-1184-E053-4EBD850A834E","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"},{"value":"NK cells","valueDescription":"Natural Killer Cell","ValueMeaning":{"publicId":"5002432","version":"1","preferredName":"Natural Killer Cell","longName":"5002432","preferredDefinition":"A type of immune cell that has granules (small particles) with enzymes that can kill tumor cells or cells infected with a virus. A natural killer cell is a type of white blood cell.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Natural Killer Cell","conceptCode":"C12536","definition":"Natural killer cells are cells that resemble large granular lymphocytes.  They do not express markers of either T or B cell lineage. They are positive for CD16, CD56, and CD 94.  These cells do possess Fc receptors for IgG and can kill target cells using antibody-dependent cell-mediated cytotoxicity. They can also use perforin to kill cells in the absence of antibody and killing may occur without previous sensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F3DCDAD-0686-3CFA-E050-BB89AD436A35","latestVersionIndicator":"Yes","beginDate":"2015-09-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-09-08","modifiedBy":"LISU","dateModified":"2023-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DDB621C8-299C-1184-E053-4EBD850A834E","beginDate":"2022-04-27","endDate":null,"createdBy":"LISU","dateCreated":"2022-04-28","modifiedBy":"ONEDATA","dateModified":"2022-04-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D9934D-48A5-2D3D-E053-F662850AF9C5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"LISU","dateModified":"2022-04-28","changeDescription":"AAML1831 - WL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"T-cell depletion method:","type":"Preferred Question Text","description":"T-cell depletion method:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Type of T-cell depletion:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D6ADE6-0B76-743B-E053-F662850A05E5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-16","modifiedBy":"KUMMEROA","dateModified":"2022-07-18","changeDescription":"AAML1831 - WL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}